Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037804
Status:
COMPLETED
Last Update Posted:
2009-08-14
First Post:
2002-05-21
Brief Title:
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None